TY - JOUR
T1 - Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients
T2 - A preliminary double-blind, randomized, controlled trial
AU - Hui, David
AU - Xu, Angela
AU - Frisbee-Hume, Susan
AU - Chisholm, Gary
AU - Morgado, Margarita
AU - Reddy, Suresh
AU - Bruera, Eduardo
N1 - Funding Information:
Dr. E. B. is supported in part by National Institutes of Health grants RO1NR010162-01A1 , RO1CA122292-01 , and RO1CA124481-01 . Dr. D. H. is supported in part by an Institutional Startup grant ( #18075582 ). This study also was supported by the M. D. Anderson Cancer Center Support Grant ( CA 016672 ). The funding sources were not involved in the conduct of the study or development of the submission. The authors declare no conflicts of interest.
PY - 2014/2
Y1 - 2014/2
N2 - Context Dyspnea is one of the most distressing symptoms in patients with cancer, and often worsens with breakthrough episodes on exertion. We hypothesized that fentanyl given prophylactically may alleviate breakthrough dyspnea. Objectives To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events. Methods In this double-blind, randomized, controlled trial, we asked ambulatory patients with breakthrough dyspnea to perform a baseline six minute walk test (6MWT), and then assigned them to either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. We documented the change in dyspnea Numeric Rating Scale (NRS) score, walk distance, vital signs, and adverse events between the first and second 6MWT. Results A total of 20 patients were enrolled (1:1 ratio) without attrition. Comparison between baseline and second walk showed that fentanyl was associated with significant improvements in dyspnea NRS score at the end of the 6MWT (mean [95% CI] -1.8 [-3.2, -0.4]), dyspnea NRS score at rest of 15 minutes after drug administration (-0.9 [-1.8, -0.04]), Borg Scale fatigue score at the end of the 6MWT (-1.3 [-2.4, -0.2]), 6MWT distance (+37.2 m [5.8, 68.6]), and respiratory rate (-2.4 [-4.5, -0.3]). Nonstatistically significant improvements also were observed in the placebo arm, with no difference between the two study arms. No significant adverse effects were observed. Conclusion Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate. We also observed a large placebo effect. Our results justify larger randomized controlled trials with higher fentanyl doses (clinicaltrials.gov registration: NCT01515566).
AB - Context Dyspnea is one of the most distressing symptoms in patients with cancer, and often worsens with breakthrough episodes on exertion. We hypothesized that fentanyl given prophylactically may alleviate breakthrough dyspnea. Objectives To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events. Methods In this double-blind, randomized, controlled trial, we asked ambulatory patients with breakthrough dyspnea to perform a baseline six minute walk test (6MWT), and then assigned them to either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. We documented the change in dyspnea Numeric Rating Scale (NRS) score, walk distance, vital signs, and adverse events between the first and second 6MWT. Results A total of 20 patients were enrolled (1:1 ratio) without attrition. Comparison between baseline and second walk showed that fentanyl was associated with significant improvements in dyspnea NRS score at the end of the 6MWT (mean [95% CI] -1.8 [-3.2, -0.4]), dyspnea NRS score at rest of 15 minutes after drug administration (-0.9 [-1.8, -0.04]), Borg Scale fatigue score at the end of the 6MWT (-1.3 [-2.4, -0.2]), 6MWT distance (+37.2 m [5.8, 68.6]), and respiratory rate (-2.4 [-4.5, -0.3]). Nonstatistically significant improvements also were observed in the placebo arm, with no difference between the two study arms. No significant adverse effects were observed. Conclusion Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate. We also observed a large placebo effect. Our results justify larger randomized controlled trials with higher fentanyl doses (clinicaltrials.gov registration: NCT01515566).
KW - Dyspnea
KW - exercise
KW - fentanyl
KW - neoplasms
KW - opioids
KW - prophylaxis
KW - randomized controlled trial
KW - subcutaneous
UR - http://www.scopus.com/inward/record.url?scp=84893714874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893714874&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2013.03.017
DO - 10.1016/j.jpainsymman.2013.03.017
M3 - Article
C2 - 23830530
AN - SCOPUS:84893714874
SN - 0885-3924
VL - 47
SP - 209
EP - 217
JO - Journal of pain and symptom management
JF - Journal of pain and symptom management
IS - 2
ER -